Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cancer stem
Show results for
Products
Services

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Cancer Stem Articles & Analysis

21 news found

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Globally, an estimated 19.3 million cancer cases occurred in 2020 alone, with a fatality rate of almost 10.0 million cancer deaths, with breast (11.7%), lung (11.4%), colorectal (10%) and prostate (7.3%) being the most fatal. ...

ByCELLINK


Beyond Cancer Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board

Beyond Cancer Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board

“I am excited to have these two accomplished oncologists join the Beyond Cancer Scientific Advisory Board,” stated Dr. Selena Chaisson, Chief Executive Officer of Beyond Cancer. ...

ByBeyond Air Inc


Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...

ByContext Therapeutics Inc.


NIH/NCI Small Business Innovation Research Grant, Awarded Fall 2019

NIH/NCI Small Business Innovation Research Grant, Awarded Fall 2019

Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...

ByNodexus Inc.


Carina Biotech appoints Cell Therapies to undertake manufacture of LGR5 CAR-T cells for clinical trial

Carina Biotech appoints Cell Therapies to undertake manufacture of LGR5 CAR-T cells for clinical trial

Highlights Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer. Carina’s CAR-T cells are targeted at LGR5, a cancer stem cell marker that is highly expressed ...

ByCarina Biotech


First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer

Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. ...

ByJSR Life Sciences, LLC


Carina Biotech to showcase its LGR5 CAR-T program at the American Association for Cancer Research (AACR) Annual Meeting

Carina Biotech to showcase its LGR5 CAR-T program at the American Association for Cancer Research (AACR) Annual Meeting

In colorectal cancer patients, LGR5+ expression has been correlated with a particularly poor prognosis. Cancer stem cells are a small sub-population of cells within a tumour with the ability to self-renew, differentiate into the many cell types of a tumour, initiate new tumours, and resist chemotherapy and radiotherapy (leading to relapses). By ...

ByCarina Biotech


Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration

Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration

Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. This represents a major step towards taking our CAR-T cell (CNA3103) into a Phase I/IIa clinical trial in patients with ...

ByCarina Biotech


Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs

Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs

In this case, the lentivirus transduces (or inserts) a group of genes to a patient’s T cells (immune cells), which turn the T cells into cancer-killing CAR-T cells targeting LGR5, a cancer stem cell marker found on colorectal cancer and other cancers. ...

ByCarina Biotech


Carina Biotech raises $5.4 million to ready LGR5 CAR-T program for advanced colorectal cancer for the clinic

Carina Biotech raises $5.4 million to ready LGR5 CAR-T program for advanced colorectal cancer for the clinic

“We know that colorectal cancer is the deadliest cancer for young Australians. We also know that there has been a nearly 190% increase in colorectal cancer cases in adolescents and young people in Australia over the last 30 years. ...

ByCarina Biotech


TVAX Biomedical Receives Fast Track Designation from the FDA

TVAX Biomedical Receives Fast Track Designation from the FDA

About TVAX Biomedical TVAX Biomedical is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. Unlike other forms ...

ByTVAX Biomedical, Inc.


ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants. ...

ByORYX GmbH & Co. KG


ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). ...

ByORYX GmbH & Co. KG


ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer. ...

ByORYX GmbH & Co. KG


Anthony Nolan - Saving the lives of people with blood cancer

Anthony Nolan - Saving the lives of people with blood cancer

Anthony Nolan saves the lives of people with blood cancer and blood disorders. For someone with blood cancer, a stem cell transplant could be their last chance of survival. Anthony Nolan is the charity that makes lifesaving connections between people with blood cancer and incredible strangers ready to donate their ...

ByKurita Water Industries Ltd


New FDA Approval for MSD’s Keytruda

New FDA Approval for MSD’s Keytruda

Keytruda or pembrolizumab, MSD’s (Merck in USA/Canada) monotherapy for metastatic small cell lung cancer (SCLC) has been granted accelerated approval by FDA. Keytruda is now indicated for metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. ...

ByIMAPAC


TVAX Biomedical Names Wayne Carter as President and CEO

TVAX Biomedical Names Wayne Carter as President and CEO

” About TVAX Biomedical TVAX Biomedical is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. ...

ByTVAX Biomedical, Inc.


Agilent Technologies Thought Leader Award Supports Cancer Stem Cell Research at Mount Sinai

Agilent Technologies Thought Leader Award Supports Cancer Stem Cell Research at Mount Sinai

The Agilent award will support ongoing cancer research conducted by Dr. Cordon-Cardo and his team. They are using a combination of genomic and proteomic technologies from Agilent to characterize tumor-initiating cells with stem-cell-like properties derived from solid tumors taken from subjects with various types of cancer. The goal of studying ...

ByAgilent Technologies, Inc.


Arsenic turns stem cells cancerous, spurring tumor growth

A growing body of evidence suggests that cancer is a stem-cell based disease. Normal stem cells are essential to normal tissue regeneration, and to the stability of organisms and processes. But cancer stem cells are thought to be the driving force for the formation, growth, and spread of tumors. ...

ByNational Institute of Environmental Health Sciences (NIEHS)


NIH-funded researchers discover genetic link to mesothelioma

Consequently, some inherited risk of breast and ovarian cancer may stem from mutations in BAP1 genes. "Also, it appears likely that other genes, in addition to BAP1, will be found to be associated with elevated risk of mesothelioma," said Testa. ...

ByNational Institute of Environmental Health Sciences (NIEHS)

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT